| 摘要 |
Disclosed herein are nuclear transport modulators, e.g CRM1 inhibitors, represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. Also disclosed is the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity. Particular examples are when ring A is a triazole and ring B is di-triflurormethyl phenyl for example: (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(3-((dimethylamino)methyl)-3-fluoroazetidin-1-yl)prop-2-en-1-one; (Z)-1-(3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acryloyl)-3-fluoroazetidine-3-carboxylic acid; and (Z)-1-(3-(aminomethyl)-3-fluoroazetidin-1-yl)-3-(3-(3,5-bis(trifluoromethyl) phenyl)-1H-1,2,4-triazol-1-yl)prop-2-en-1-one. |
